other material
confidence high
sentiment negative
materiality 0.60
BTIG terminates $50M at-the-market sales agreement with Matinas BioPharma
Matinas BioPharma Holdings, Inc.
- BTIG terminated the ATM sales agreement effective July 23, 2026, under Section 12(a).
- The agreement allowed Matinas to sell up to $50M of common stock through BTIG.
- No termination penalties or expenses incurred by the company.
- Matinas loses access to this equity financing facility.